Arch Biopartners Inc. (ARCH.V)
CAD 1.7
(-2.86%)
CAD 1.7
(-2.86%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -0.05 CAD | -206.32% |
| 2022 | -0.02 CAD | 8.9% |
| 2021 | -0.02 CAD | 75.26% |
| 2020 | -0.08 CAD | -92.04% |
| 2019 | -0.04 CAD | 28.34% |
| 2018 | -0.06 CAD | -60.74% |
| 2017 | -0.03 CAD | -84.66% |
| 2016 | -0.02 CAD | -18.13% |
| 2015 | -0.02 CAD | -97.53% |
| 2014 | -0.01 CAD | -102.5% |
| 2013 | -0.00 CAD | 42.03% |
| 2012 | -0.01 CAD | 26.6% |
| 2011 | -0.01 CAD | 93.73% |
| 2010 | -0.15 CAD | 16.67% |
| 2009 | -0.18 CAD | -646.89% |
| 2008 | -0.02 CAD | -82.58% |
| 2007 | -0.01 CAD | -1785.71% |
| 2006 | -0.00 CAD | 91.03% |
| 2005 | -0.01 CAD | 71.74% |
| 2004 | -0.03 CAD | -72.5% |
| 2003 | -0.02 CAD | 57.1% |
| 2002 | -0.04 CAD | 90.44% |
| 2001 | -0.39 CAD | -14.71% |
| 2000 | -0.34 CAD | -30.77% |
| 1999 | -0.26 CAD | -36.84% |
| 1998 | -0.19 CAD | 71.21% |
| 1997 | -0.66 CAD | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q1 | -0.01 CAD | -420.51% |
| 2024 Q3 | -0.01 CAD | 22.95% |
| 2024 Q2 | -0.02 CAD | -46.4% |
| 2023 Q3 | -0.01 CAD | 49.3% |
| 2023 FY | - CAD | -206.32% |
| 2023 Q4 | 0.00 CAD | 154.17% |
| 2023 Q2 | -0.01 CAD | 56.57% |
| 2023 Q1 | -0.03 CAD | -473.68% |
| 2022 Q1 | -0.00 CAD | -125.45% |
| 2022 Q3 | -0.00 CAD | 52.24% |
| 2022 FY | - CAD | 8.9% |
| 2022 Q4 | -0.01 CAD | -78.13% |
| 2022 Q2 | -0.01 CAD | -139.29% |
| 2021 Q2 | -0.02 CAD | 36.76% |
| 2021 FY | - CAD | 75.26% |
| 2021 Q4 | 0.01 CAD | -21.43% |
| 2021 Q3 | 0.01 CAD | 181.4% |
| 2021 Q1 | -0.03 CAD | -2.64% |
| 2020 Q3 | -0.04 CAD | -2181.25% |
| 2020 Q1 | -0.01 CAD | 24.85% |
| 2020 FY | - CAD | -92.04% |
| 2020 Q4 | -0.03 CAD | 27.4% |
| 2020 Q2 | -0.00 CAD | 87.1% |
| 2019 Q4 | -0.02 CAD | -1078.57% |
| 2019 Q3 | -0.00 CAD | 84.09% |
| 2019 FY | - CAD | 28.34% |
| 2019 Q2 | -0.01 CAD | 37.14% |
| 2019 Q1 | -0.01 CAD | -4.48% |
| 2018 Q2 | -0.01 CAD | -67.74% |
| 2018 Q1 | -0.01 CAD | -55.0% |
| 2018 FY | - CAD | -60.74% |
| 2018 Q4 | -0.01 CAD | 47.86% |
| 2018 Q3 | -0.03 CAD | -147.12% |
| 2017 Q4 | -0.00 CAD | 83.19% |
| 2017 Q3 | -0.02 CAD | -750.0% |
| 2017 FY | - CAD | -84.66% |
| 2017 Q1 | -0.00 CAD | 31.25% |
| 2017 Q2 | -0.00 CAD | 36.36% |
| 2016 Q3 | -0.00 CAD | 44.26% |
| 2016 FY | - CAD | -18.13% |
| 2016 Q1 | -0.00 CAD | -7.41% |
| 2016 Q2 | -0.01 CAD | -110.34% |
| 2016 Q4 | -0.01 CAD | -88.24% |
| 2015 FY | - CAD | -97.53% |
| 2015 Q2 | -0.00 CAD | 54.29% |
| 2015 Q3 | -0.00 CAD | 3.13% |
| 2015 Q4 | -0.00 CAD | 12.9% |
| 2015 Q1 | -0.01 CAD | -125.81% |
| 2014 Q1 | -0.00 CAD | 8.33% |
| 2014 Q2 | -0.00 CAD | -9.09% |
| 2014 Q4 | -0.00 CAD | -19.23% |
| 2014 FY | - CAD | -102.5% |
| 2014 Q3 | -0.00 CAD | -116.67% |
| 2013 Q2 | -0.00 CAD | -142.86% |
| 2013 Q4 | -0.00 CAD | -200.0% |
| 2013 Q1 | -0.00 CAD | 63.16% |
| 2013 Q3 | -0.00 CAD | 76.47% |
| 2013 FY | - CAD | 42.03% |
| 2012 Q2 | -0.00 CAD | 27.78% |
| 2012 Q4 | -0.00 CAD | 0.0% |
| 2012 FY | - CAD | 26.6% |
| 2012 Q3 | -0.00 CAD | -46.15% |
| 2012 Q1 | -0.00 CAD | 5.26% |
| 2011 Q4 | -0.00 CAD | 48.65% |
| 2011 FY | - CAD | 93.73% |
| 2011 Q3 | -0.00 CAD | -131.25% |
| 2011 Q2 | -0.00 CAD | 30.43% |
| 2011 Q1 | -0.00 CAD | -35.29% |
| 2010 Q2 | -0.00 CAD | 75.68% |
| 2010 FY | - CAD | 16.67% |
| 2010 Q4 | -0.00 CAD | 98.87% |
| 2010 Q3 | -0.15 CAD | -16566.67% |
| 2010 Q1 | -0.00 CAD | -270.0% |
| 2009 Q4 | -0.00 CAD | 99.47% |
| 2009 FY | - CAD | -646.89% |
| 2009 Q2 | -0.01 CAD | 46.43% |
| 2009 Q3 | -0.19 CAD | -3066.67% |
| 2009 Q1 | -0.01 CAD | -2700.0% |
| 2008 Q4 | -0.00 CAD | 93.75% |
| 2008 Q3 | -0.01 CAD | 4.48% |
| 2008 FY | - CAD | -82.58% |
| 2008 Q2 | -0.01 CAD | 10.67% |
| 2008 Q1 | -0.01 CAD | -275.0% |
| 2007 Q2 | -0.00 CAD | -132.88% |
| 2007 FY | - CAD | -1785.71% |
| 2007 Q4 | -0.00 CAD | -66.67% |
| 2007 Q3 | -0.00 CAD | 50.0% |
| 2007 Q1 | 0.01 CAD | 431.82% |
| 2006 FY | - CAD | 91.03% |
| 2006 Q4 | -0.00 CAD | -15.79% |
| 2006 Q3 | -0.00 CAD | 17.39% |
| 2006 Q2 | -0.00 CAD | 41.03% |
| 2006 Q1 | -0.00 CAD | -244.44% |
| 2005 Q2 | -0.00 CAD | 78.7% |
| 2005 Q1 | -0.02 CAD | -116.67% |
| 2005 FY | - CAD | 71.74% |
| 2005 Q4 | 0.00 CAD | 190.0% |
| 2005 Q3 | -0.00 CAD | 16.67% |
| 2004 FY | - CAD | -72.5% |
| 2004 Q1 | -0.01 CAD | 31.13% |
| 2004 Q2 | -0.00 CAD | 61.64% |
| 2004 Q3 | -0.00 CAD | -39.29% |
| 2004 Q4 | -0.01 CAD | -100.0% |
| 2003 Q1 | -0.02 CAD | -608.7% |
| 2003 FY | - CAD | 57.1% |
| 2003 Q4 | -0.01 CAD | -523.53% |
| 2003 Q3 | -0.00 CAD | 81.72% |
| 2003 Q2 | -0.01 CAD | 42.94% |
| 2002 FY | - CAD | 90.44% |
| 2002 Q3 | -0.01 CAD | 4.31% |
| 2002 Q4 | -0.00 CAD | 79.28% |
| 2002 Q1 | -0.33 CAD | -2191.67% |
| 2002 Q2 | -0.01 CAD | 96.48% |
| 2001 Q4 | -0.01 CAD | 65.96% |
| 2001 Q3 | -0.04 CAD | -471.62% |
| 2001 Q2 | -0.01 CAD | 91.24% |
| 2001 Q1 | -0.08 CAD | -14.81% |
| 2001 FY | - CAD | -14.71% |
| 2000 Q2 | -0.02 CAD | 89.67% |
| 2000 FY | - CAD | -30.77% |
| 2000 Q1 | -0.18 CAD | -402.79% |
| 2000 Q4 | -0.07 CAD | 22.36% |
| 2000 Q3 | -0.09 CAD | -409.68% |
| 1999 Q4 | -0.04 CAD | 34.79% |
| 1999 FY | - CAD | -36.84% |
| 1999 Q1 | -0.22 CAD | -1494.2% |
| 1999 Q2 | -0.03 CAD | 86.55% |
| 1999 Q3 | -0.05 CAD | -85.47% |
| 1998 FY | - CAD | 71.21% |
| 1998 Q4 | -0.01 CAD | 56.74% |
| 1998 Q2 | -0.03 CAD | 0.0% |
| 1998 Q3 | -0.03 CAD | 0.0% |
| 1997 FY | - CAD | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| Covalon Technologies Ltd. | -0.18 CAD | 70.389% |
| Hemostemix Inc. | -0.03 CAD | -75.908% |
| Universal Ibogaine Inc. | -0.06 CAD | 5.664% |
| Kane Biotech Inc. | -0.04 CAD | -48.468% |
| MedMira Inc. | -0.00 CAD | -1302.632% |
| Marvel Biosciences Corp. | -0.06 CAD | 7.785% |
| NervGen Pharma Corp. | -0.38 CAD | 85.974% |
| XORTX Therapeutics Inc. | -1.44 CAD | 96.299% |